Macro Dynamics - As of the end of October, the broad money supply (M2) reached 335.13 trillion yuan, with a year-on-year growth of 8.2% [2] - The narrow money supply (M1) stood at 112 trillion yuan, growing by 6.2% year-on-year [2] - The currency in circulation (M0) was 13.55 trillion yuan, reflecting a year-on-year increase of 10.6% [2] - A net cash injection of 728.4 billion yuan occurred in the first ten months of the year [2] Financial Regulation - The Financial Regulatory Bureau is set to release a revised "Commercial Bank Merger Loan Management Measures" to support mergers and restructuring, including for tech enterprises [3] - The Bureau is collaborating with other departments to develop policies that promote high-quality development in technology insurance, providing better economic support for tech activities [3] Market Data - On November 13, the Shanghai Composite Index rose by 0.73%, reaching a ten-year high, with over 100 stocks hitting the daily limit [9] - The Shenzhen Component Index increased by 1.78%, and the ChiNext Index rose by 2.55% [9] - The total trading volume in the Shanghai and Shenzhen markets was 2.04 trillion yuan, an increase of 969 billion yuan from the previous trading day [9] Company Dynamics - China Pacific Insurance reported a premium income of 241.32 billion yuan for its life insurance subsidiary from January to October, a year-on-year increase of 9.9% [7] - Tencent Holdings announced third-quarter revenue of 192.87 billion yuan, a 15% year-on-year increase, with net profit attributable to shareholders rising by 19% [12] - Bilibili reported a third-quarter adjusted net profit of 786 million yuan, a significant increase of 233% year-on-year, with total revenue reaching 7.69 billion yuan [14] - Semiconductor manufacturer SMIC reported a net profit growth of 41.1% year-on-year for the first three quarters, with revenue of 49.51 billion yuan [15] - Kanda New Materials announced the termination of its acquisition of North One Semiconductor due to unmet expectations in transaction progress [18]

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

人民财讯11月13日电，康达新材（002669）11月13日公告，公司此前公告与北一半导体科技(广东)有限 公司(简称"北一半导体")及其股东签署了《收购意向协议》，拟通过现金方式收购北一半导体不低于 51%的股权，取得其控股权。《收购意向协议》签署后，公司有序开展了尽职调查、审计等工作，但前 述工作进展未及预期，且交易各方就交易进程未能达成共识。公司决定终止此次收购，交易各方于11月 13日签署了《收购终止协议》。 ...

证券代码：002669 证券简称：康达新材 公告编号：2025-118 康达新材料（集团）股份有限公司 关于终止筹划收购股权的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、筹划股权收购的概述 康达新材料（集团）股份有限公司（以下简称"公司"或"康达新材"）于 2025 年 8 月 28 日与北一半导体科技（广东）有限公司（以下简称"北一半导体"）及 其股东北芯科技（天津）有限公司、YU UNYONG（韩国籍自然人）签署了《收 购意向协议》，拟通过现金方式收购北一半导体不低于 51%的股权，取得其控股 权，具体内容详见公司于 2025 年 8 月 29 日披露的《关于筹划收购北一半导体科 技（广东）有限公司控股权暨签署<收购意向协议>的公告》（公告编号：2025-100）。 二、终止本次筹划收购事项的情况说明 《收购意向协议》签署后，公司有序开展了尽职调查、审计等工作，但前述 工作进展未及预期，且交易各方就交易进程未能达成共识。为维护公司及全体股 东的合法权益，经公司审慎研究，决定终止本次收购。交易各方于 2025 年 11 月 13 日签署了《收购 ...

格隆汇11月13日丨康达新材(002669.SZ)公布，公司于2025年8月28日与北一半导体科技（广东）有限公 司（简称"北一半导体"）及其股东北芯科技（天津）有限公司、YUUNYONG（韩国籍自然人）签署了 《收购意向协议》，拟通过现金方式收购北一半导体不低于51%的股权，取得其控股权，具体内容详见 公司于2025年8月29日披露的《关于筹划收购北一半导体科技（广东）有限公司控股权暨签署 <收购意 向协议> 的公告》。《收购意向协议》签署后，公司有序开展了尽职调查、审计等工作，但前述工作进 展未及预期，且交易各方就交易进程未能达成共识。为维护公司及全体股东的合法权益，经公司审慎研 究，决定终止本次收购。交易各方于2025年11月13日签署了《收购终止协议》。 ...

智通财经APP讯，康达新材(002669.SZ)发布公告，公司于2025 年8月28日与北一半导体科技(广东)有限 公司(以下简称"北一半导体")及其股东北芯科技(天津)有限公司、YUUNYONG(韩国籍自然人)签署了 《收购意向协议》，拟通过现金方式收购北一半导体不低于51%的股权，取得其控股权。 《收购意向协议》签署后，公司有序开展了尽职调查、审计等工作，但前述工作进展未及预期，且交易 各方就交易进程未能达成共识。为维护公司及全体股东的合法权益，经公司审慎研究，决定终止本次收 购。交易各方于2025年11 月13日签署了《收购终止协议》。 ...

格隆汇11月13日丨康达新材(002669.SZ)公布，公司于2025年8月28日与北一半导体科技（广东）有限公 司（简称"北一半导体"）及其股东北芯科技（天津）有限公司、YUUNYONG（韩国籍自然人）签署了 《收购意向协议》，拟通过现金方式收购北一半导体不低于51%的股权，取得其控股权，具体内容详见 公司于2025年8月29日披露的《关于筹划收购北一半导体科技（广东）有限公司控股权暨签署的公 告》。《收购意向协议》签署后，公司有序开展了尽职调查、审计等工作，但前述工作进展未及预期， 且交易各方就交易进程未能达成共识。为维护公司及全体股东的合法权益，经公司审慎研究，决定终止 本次收购。交易各方于2025年11月13日签署了《收购终止协议》。 ...

康达新材公告称，公司于2025年8月28日与北一半导体及其股东签署《收购意向协议》，拟现金收购其 不低于51%股权获控股权。但尽职调查、审计等工作进展未达预期，交易各方就进程未达成共识。为维 护股东权益，公司决定终止收购，各方于11月13日签署《收购终止协议》。此次终止无违约追责情形， 对公司生产经营、财务状况无重大不利影响，不影响未来战略规划。 ...

Group 1 - The core point of the announcement is that the controlling shareholder, Tangshan Industrial Holding Group Co., Ltd., has extended the repurchase period for a portion of its pledged shares due to its funding needs, and its credit status is good, indicating it has the ability to fulfill its obligations [1][2] - As of the announcement date, there are no risks of forced liquidation, freezing, or auction of the pledged shares, and this situation will not lead to a change in the company's actual control or affect its operations and governance [2] - The company will continue to monitor the shareholder's pledge situation and related risks, ensuring compliance with relevant laws and regulations for timely information disclosure [2] Group 2 - The company has approved the temporary use of idle raised funds amounting to no more than 45 million yuan to supplement its working capital, with a usage period not exceeding twelve months [6] - As of November 11, 2025, the company has fully repaid the 45 million yuan back to the special account for raised funds, and this repayment was completed within the stipulated time frame [7]

证券代码：002669 证券简称：康达新材 公告编号：2025-116 康达新材料（集团）股份有限公司 关于归还用于暂时补充流动资金的闲置募集资金的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 康达新材料（集团）股份有限公司（以下简称"公司"）于2024年11月25 日召开第五届董事会第三十八次会议、第五届监事会第三十一次会议审议通过了 《关于使用部分闲置募集资金暂时补充流动资金的议案》，董事会、监事会同意 公司在确保不影响募集资金投资项目建设和募集资金使用的情况下，使用不超过 4,500万元的闲置募集资金暂时补充流动资金，使用期限自董事会、监事会审议 通过之日起不超过十二个月（2024年11月25日——2025年11月24日）。具体内容 详见2024年11月26日在巨潮资讯网上披露的《关于使用部分闲置募集资金暂时补 充流动资金的公告》（公告编号：2024-104）。 在上述授权额度及期限内，根据募集资金使用安排，公司实际用于暂时补充 流动资金的闲置募集资金共计4,500万元。公司对该部分资金进行了合理的安排 与使用，没有影响募集资金使用计划的正常进行 ...